Lion TCR’s Liocyx-M004 Approved for Global Phase 2 HBV Liver Cancer Trial
February 12, 2025
Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate